Company/Organization profile
This webpage lists RDCRN funding sources.
The Rare Diseases Clinical Research Network (RDCRN) program advances medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing. Through the network, scientists from multiple disciplines at hundreds of clinical sites around the world work together with patients and patient advocacy groups to study more than 280 rare diseases.
The RDCRN is designed to promote highly collaborative, multi-site, patient-centric, translational and clinical research. The Rare Diseases Clinical Research Consortia (RDCRCs) focus on unmet clinical trial readiness needs that will move the field of research forward from its current state.
The RDCRN facilitates clinical research in rare diseases through support for:
– Collaborative activities, including multisite longitudinal studies of individuals with rare diseases and/or clinical trials.
– Career enhancement – encouraging the next generation of rare disease researchers.
– Pilot and feasibility projects
– Data management to facilitate high quality data standards, collection, storage and sharing
– Clinical research support
– Access to information about rare diseases for basic and clinical researchers, academic and practicing physicians, patients, and the public.
The RDCRN was established by the NIH Office of Rare Diseases in 2003 and the program is now coordinated by NCATS. Since its launch, nearly 40,000 patients have been enrolled in network clinical studies. The network is composed of about 2,600 researchers, including scientific program staff from NCATS and collaborating NIH components, academic investigators, and members of 130 patient advocacy groups.